pntd.0010159.g005.tif (899.25 kB)
The 8 benzimidazole carbamates from the Pathogen Box, Stasis Box and Pandemic Response Box tested for M. mycetomatis.
figure
posted on 2022-02-04, 18:36 authored by Wilson Lim, Bertrand Nyuykonge, Kimberly Eadie, Mickey Konings, Juli Smeets, Ahmed Fahal, Alexandro Bonifaz, Matthew Todd, Benjamin Perry, Kirandeep Samby, Jeremy Burrows, Annelies Verbon, Wendy van de SandeOnly three benzimidazole carbamates, MMV1782387, MMV0031343 (fenbendazole) and MMV344625 (carbendazim) were tested in vivo, while the rest wasn’t able to inhibit M. mycetomatis growth at 25μM. Due to MMY1782387 and fenbendazole’s efficacy in vivo, benzimidazole carbamates are a promising group of compounds to investigate as part of the MycetOS initiative in search for novel drugs to treat eumycetoma.
History
Usage metrics
Categories
Keywords
pandemic response boxminimal inhibitory concentrationsmedicinal chemistry optimisationfungal orders sordarialesaminoquinolone derivative tafenoquinemadurella tropicana madurella pseudomycetomatis galleria mellonella find novel drugsfalciformispora senegalensis div >< pseven inhibited growthpromising drug candidatesmadurella mycetomatis benzimidazole carbamates fenbendazoleeumycetoma promising candidatesmycetomatis vivo vitro novel antifungalstreat eumycetomasignificantly prolongmycetos ).medicopsis romeroilike moleculeslarvae survivalfour compoundsfive speciescure ratescompounds activealso serve26 compounds
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC